Tanespimycina Uses, Dosage, Side Effects and more
Tanespimycina, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.
| Trade Name | Tanespimycina |
| Generic | Tanespimycin |
| Tanespimycin Other Names | 17AAG, Tanespimycin, tanespimycina |
| Type | |
| Formula | C31H43N3O8 |
| Weight | Average: 585.698 Monoisotopic: 585.305015357 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in leukemia (myeloid) and solid tumors.
How Tanespimycina works
Tanespimycina is a small molecule inhibitor of heat shock protein 90 (HSP90). HSP90 is a molecular “chaperone” protein that controls protein shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells.
